

**Amendments in the Claims**

- 1-10. (Canceled).
11. (Previously presented) The method as claimed in claim 16, wherein the mammal is man.
12. (Previously presented) The method as claimed in claim 16, wherein the transgenic cells are transfected by means of a recombinant adenovirus vector.
- 13-15. (Canceled).
16. (Currently amended) A method for expressing a transgenic product by transgenic cells in a mammal comprising introducing into a cells of said mammal a transgene by a single administration of a vector, wherein said transgenic cells are produced *in vivo* and are capable of expressing said transgenic product, and administering to said mammal an immunosuppressant comprising p15-deoxyspergualin, anti-T-cell antibody, corticosteroid, azathioprine, or methotrexate in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 50% greater than the level of said product when said immunosuppressant is not administered, wherein said immunosuppressant is administered before, during, or after, or any combination thereof, administration of the ~~transgenic product~~ transgene into the mammal.
17. (Previously presented) The method of Claim 16 wherein said immunosuppressant is administered in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 5 times greater than the level of said product when said immunosuppressant is not administered.

18. (Previously presented) The method of Claim 16 wherein said immunosuppressant is administered in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 10 times greater than the level of said product when said immunosuppressant is not administered.
19. (Withdrawn) A method for identifying a substance which has immunosuppressant properties and which remains capable, after its administration to a mammal has been discontinued, of suppressing the immune response of said mammal to a transgenic cell which is contained in the mammal and which expresses a transgenic product, said method comprising the step of comparing the level of said transgenic product produced by a transgenic cell contained in a first mammal which has been administered said substance with the level of said transgenic product produced by a transgenic cell contained in a second mammal which has not been administered said substance, said levels being measured after the administration of said substance has been discontinued.
20. (Withdrawn) A method according to Claim 19 wherein the level of said transgenic product in said first and second mammals is measured 15 or more days after the administration of said substance has been discontinued.
21. (Withdrawn) A method according to Claim 19 wherein said transgenic cell is produced *in vivo* in said first and second mammals and the level of said transgenic product in said first and second
23. (Previously presented) The method according to Claim 16 wherein said immunosuppressant is p15-deoxyspergualin.
24. (Canceled).

25. (Currently amended) The method according to Claim 16 wherein said immunosuppressant is administered intravenously or intraperitoneally.
26. (Currently amended) A method for increasing the tolerance of a mammal to transgenic cells, wherein the transgenic cells are produced *in vivo* after ~~the~~ a single administration of a vector including a transgene, by administering an immunosuppressant comprising p15-deoxyspergualin, anti-T-cell antibody, corticosteroid, azathioprine, or methotrexate to the mammal intravenously or intraperitoneally ~~in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 50% greater than the level of said product when said immunosuppressant is not administered, wherein said immunosuppressant is administered, before, during, or after, or any combination thereof, the administration of the vector.~~
27. (Previously presented) The method according to Claim 26 wherein said immunosuppressant is p15-deoxyspergualin.
28. (Currently amended) The method according to Claim 26 wherein said immunosuppressant is administered ~~intravenously~~ intraperitoneally.
29. (Currently amended) A method for increasing the tolerance of a mammal to transgenic cells comprising introducing into a cell of said mammal a transgene capable of expressing ~~said a~~ transgenic product, introducing said transgenic cells into said mammal, and administering to said mammal an immunosuppressant comprising p15-deoxyspergualin, anti-T-cell antibody, corticosteroid, azathioprine, or methotrexate ~~in an amount such that the level of said transgenic product, as measured 15 days following the discontinuation of said administration of said immunosuppressant, is at least 50% greater than the level of said product when said immunosuppressant is not administered, wherein said immunosuppressant is~~

administered before, during, or after, or any combination thereof, administration of the transgenic cells.

30. (Previously presented) The method according to Claim 29 wherein said immunosuppressant is p15-deoxyspergualin.
31. (Canceled)
32. (Currently amended) The method according to Claim 29 wherein said immunosuppressant is administered intravenously or intraperitoneally.